penile%20cancer
PENILE CANCER

Penile cancer is a rare type of malignant growth that occurs on the skin or tissues of the penis.

It often presents as a palpable visible penile lesion w/ signs that may include pain, bleeding, discharge or a foul odor.

The lesion may be fungating, nodular or ulcerative and may be concealed by phimosis.


Differential Diagnosis

  • There are several differential diagnoses that need to be ruled out & these include infectious, inflammatory, premalignant & malignant etiologies:
    • Infectious: Genital herpes, primary syphilis
    • Inflammatory: Angiokeratomas, genital psoriasis, lichen planus
    • Premalignant: Condyloma acuminata, cutaneous horn, leukoplakia, lichen sclerosis or balanitis xerotica obliterans, pseudoepitheliomatous keratotic & micaceous balanitis (PKMB)
    • Malignant: Basal cell carcinoma, Kaposi sarcoma, malignant melanoma, urethral carcinoma, metastasis from another primary tumor site
  • Refer patient for further investigation & appropriate treatment
Editor's Recommendations
Most Read Articles
5 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
4 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
2 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.